Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (77)

II-01Esther Encinas

Population pharmacokinetic modelling of the antihistamine bilastine in children within the context of a model informed paediatric drug development approach

Wednesday 15:50-17:20

II-02Aline Engbers

Pharmacokinetics of ibuprofen in very preterm infants with patent ductus arteriosus

Wednesday 15:50-17:20

II-03Elvira Erhardt

Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model

Wednesday 15:50-17:20

II-04Ruben Faelens

Benefits of TDM in clinical management: a test case in infliximab for ulcerative colitis

Wednesday 15:50-17:20

II-05Dzhem Farandzha

Tacrolimus Population Pharmacokinetic Analysis with Pmetrics in Infants after Liver Transplantation – preliminary data.

Wednesday 15:50-17:20

II-06

Bayesian hierarchical model of oscillatory cortisol response during drug intervention

Wednesday 15:50-17:20

II-07Kevin Feng

Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies

Wednesday 15:50-17:20

II-08Yan Feng

A Mixture Tumor Growth Dynamic (TGD) Model to Describe Differential Patterns of Longitudinal Tumor Response of Advanced Melanoma Patients Treated with Ipilimumab

Wednesday 15:50-17:20

II-09Fernandez Teruel Carlos

Drug exposure / response model for neutropenia with lurbinectedin in cancer patients

Wednesday 15:50-17:20

II-10Martin Fink

Informative study designs: The value of within-subject dose-escalation in the ‘Espresso design’

Wednesday 15:50-17:20

II-11Chiara Fornari

Development of a haematopoiesis systems pharmacology model for prediction of carboplatin induced bone marrow toxicity

Wednesday 15:50-17:20

II-12Jose Francis

AADAC gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis

Wednesday 15:50-17:20

II-13Thomas Frank

LaTeX-based report writing: 10 years’ experience from Sanofi’s M&S group in Germany

Wednesday 15:50-17:20

II-14Sebastian Frechen

A technical concept of automatic PBPK platform (re-)qualification in the Open Systems Pharmacology Suite (PK-Sim® and MoBi®)

Wednesday 15:50-17:20

II-15Matthias Frei

Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions

Wednesday 15:50-17:20

II-16Svetlana Freiberga

Understanding sources of variability: The variability attribution plot

Wednesday 15:50-17:20

II-17Nicolas Frey

Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis

Wednesday 15:50-17:20

II-18Fiona G. Gao

Prediction of human pharmacokinetics of subcutaneously administered depot formulation using MBPK model

Wednesday 15:50-17:20

II-19Silke Gastine

Nonparametric Pharmacokinetic-Pharmacodynamic Modelling of Posaconazole

Wednesday 15:50-17:20

II-20Florence Gattacceca

Pharmacokinetic-Pharmacodynamic (PKPD) model of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine

Wednesday 15:50-17:20

II-21Wei Gao

Viral Dynamics Model Predicts Clinical Efficacy in Hepatitis C Virus (HCV) Infected Patients Using Viral Kinetic Data from Phase 1 Studies

Wednesday 15:50-17:20

II-22Glenn Gauderat

Reversing resistance to anticancer treatment supported by pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in xenograft mice

Wednesday 15:50-17:20

II-23Francois Gaudreault

Model based Phase 2 Dose Selection of BIIB059 in Subjects with Systemic and Cutaneous Lupus Erythematosus (SLE and CLE)

Wednesday 15:50-17:20

II-24Kamunkhwala Gausi

methodological characterization of qt/qtc in children with severe malaria anaemia receiving arthemether-lumefantrine preceded by quinine

Wednesday 15:50-17:20

II-25

Integrated novel modelling framework for evaluating the efficacy and cost effectiveness of novel pharmaceutical agents in stroke prevention

Wednesday 15:50-17:20

II-26Eva Germovsek

An exposure-response model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy formulations

Wednesday 15:50-17:20

II-27Anais Glatard

Population pharmacokinetic model of amisulpride for individual dosing in psychiatric patients

Wednesday 15:50-17:20

II-28Nathalie Gobeau

Model-based informed screening of antimalarial combinations

Wednesday 15:50-17:20

II-29Nele Goeyvaerts

Population Pharmacokinetic/Pharmacodynamic of a Toll-Like-Receptor 7 (TLR7) Agonist that Induces IP-10 and ISG15 in Cynomolgus Monkeys

Wednesday 15:50-17:20

II-30Antonio Goncalves

Modelling hepatitis B kinetics in mice treated by a novel TLR-7 agonist, alone or in combination with entecavir

Wednesday 15:50-17:20

II-31Ignacio Gonzalez-Garcia

Exploration of different scenarios using a drug exposure-response model of Lurbinectedin

Wednesday 15:50-17:20

II-32Kosalaram Goteti

Drug-disease model describing the effect of intraarticular injected sprifermin on cartilage thickness measured by magnetic resonance imaging in osteoarthritis patients

Wednesday 15:50-17:20

II-33Verena Gotta

Modelling urea clearance in pediatric and young adult patients on chronic hemodialysis

Wednesday 15:50-17:20

II-34Sebastiaan Goulooze

Supervised item response theory modelling improves prediction of iatrogenic withdrawal in children

Wednesday 15:50-17:20

II-35Silvia Grandoni

Evaluating the inclusion of the particle size distribution in the lung dissolution model of a WB-PBPK model to describe the pharmacokinetics of inhaled polydisperse drugs.

Wednesday 15:50-17:20

II-36Hans Peter Grimm

PK Projections for Therapeutic Proteins in Entry Into Human Studies: Roche pRED Experience From 2004 to 2016

Wednesday 15:50-17:20

II-37Ana-Marija Grisic

Towards a comprehensive PK/PD model of infliximab in inflammatory bowel diseases, with support of prior knowledge

Wednesday 15:50-17:20

II-38Felix Hammann

Whole-body physiology pharmacokinetic modeling of flip-flop behavior of oral oxycodone solution in pediatric patients 5-16 years old

Wednesday 15:50-17:20

II-39Niklas Hartung

A size- and location-structured model for pulmonary absorption, elimination and dissolution of an orally inhaled drug

Wednesday 15:50-17:20

II-40Emilie Hénin

Individual therapeutic monitoring strategy of a factor IX concentrate (OCTAFIX ®) for prophylaxis in patients with haemophilia B, using population modelling approaches

Wednesday 15:50-17:20

II-41Andrea Henrich

Mixed effects modeling of concentration-QT relationships: first experiences with the new white paper

Wednesday 15:50-17:20

II-42Eef Hoeben

Modelling the Transfer of Sildenafil Across the Placenta with Data of an Ex-Vivo Human Placenta Perfusion Experiment

Wednesday 15:50-17:20

II-43Nick Holford

Using Biomarkers to Predict the Target Dose of Warfarin and Linezolid

Wednesday 15:50-17:20

II-44Richard Hooijmaijers

ShinyMixR: A project-centric R/Shiny run management tool for nlmixr

Wednesday 15:50-17:20

II-45Andrew Hooker

Computation of the geometric mean and variance of the AUC using polynomial chaos

Wednesday 15:50-17:20

II-46Joy Hsu

Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for the Confirmation of Alectinib 600 mg BID Dose Regimen in the Global ALK Inhibitor-Naïve Population

Wednesday 15:50-17:20

II-47Wilhelm Huisinga

Cell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment

Wednesday 15:50-17:20

II-48Hwi-yeol Yun

Accurate and Precise Prediction of in-vivo hepatic clearance for drug with low KM

Wednesday 15:50-17:20

II-49Moustafa M. A. Ibrahim

Model-based post-processing of CWRES for assessment of prediction bias

Wednesday 15:50-17:20

II-50Ibrahim Ince

A Population Physiologically-Based Pharmacokinetic Model for prediction of pharmacokinetics of small molecule drugs in healthy Japanese adults: Bridging PBPK from Caucasian to Japanese ethnicity

Wednesday 15:50-17:20

II-51Mohamed Ismail

An open source software solution for automating pharmacokinetic/pharmacodynamic model selection

Wednesday 15:50-17:20

II-52Julie Janssen

Semi-physiological Pharmacokinetics of Bortezomib in Pediatric Patients with Acute Lymphoblastic Leukemia

Wednesday 15:50-17:20

II-53David Janzén

Estimating absolute bioavailability in population models despite lacking IV data

Wednesday 15:50-17:20

II-54Petra Jauslin

Population Pharmacokinetic Analysis of Tildrakizumab, an Anti-IL-23 Antibody, in Healthy Volunteers and Subjects with Psoriasis

Wednesday 15:50-17:20

II-55Garrit Jentsch

A repeated time-to-event model is superior to a count regression analysis in linking FVIII activity to bleeding events in prophylactically treated patients with severe haemophilia A

Wednesday 15:50-17:20

II-56Jane Knöchel

Focusing on the essential dynamics of systems pharmacology models by exploiting an input-response characterisation

Wednesday 15:50-17:20

II-57Martin Johnson

Artificial neural networks can facilitate the analysis and prediction of longitudinal tumour size data: an example from a non-small cell lung cancer phase III study

Wednesday 15:50-17:20

II-58Koen Jolling

Population pharmacokinetic modelling of CHF6001 following dry powder inhalation in healthy volunteers.

Wednesday 15:50-17:20

II-59Fredrik Jonsson

Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients

Wednesday 15:50-17:20

II-60Niclas Jonsson

Increasing the efficiency of the covariate search algorithm in the SCM

Wednesday 15:50-17:20

II-61Siv Jonsson

Sample size for detection of drug effect using item level and total score models for Unified Parkinson’s Disease Rating Scale data

Wednesday 15:50-17:20

II-62Felix Jost

Gauss-Newton algorithm for parameter estimation of nonlinear mixed-effects models

Wednesday 15:50-17:20

II-63Astrid Jullion

Dosing Regimen selection supported by population PKPD model of thrombocytopenia

Wednesday 15:50-17:20

II-64Yunseob Jung

A population pharmacokinetic model of methotrexate in Korean people

Wednesday 15:50-17:20

II-65Fabian Jung

Evaluation of release techniques for nanocarriers on the basis of IVIVC-PBPK modeling

Wednesday 15:50-17:20

II-66Tobias Kanacher

Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors

Wednesday 15:50-17:20

II-67Iasonas Kapralos

Population Pharmacokinetics of Anidulafungin in ICU patients

Wednesday 15:50-17:20

II-68Eleni Karatza

Mathematical modeling of gastric emptying: a joint model for losartan and its active metabolite EXP-3174

Wednesday 15:50-17:20

II-69Yuri Kheifetz

Integral individualized model of hematopoiesis explains and predicts joint dynamics of thrombocytes, granulocytes and lymphocytes under different chemotherapeutic and adjuvant treatments scenarios

Wednesday 15:50-17:20

II-70Yun Kim

A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects and patients

Wednesday 15:50-17:20

II-71Yu Kyong Kim

A Prospective Population Pharmacokinetic Study for Recommendation of Prophylactic Fluconazole Dosage Regimen in Preterm Infants

Wednesday 15:50-17:20

II-72Hyungsub Kim

Pharmacokinetic and pharmacodynamic modeling of 10% intravenous immunoglobulin and glucocorticoids for adult patients with immune thrombocytopenia

Wednesday 15:50-17:20

II-73Anne Kümmel

Building predictive longitudinal PKPD models of antimalarial combinations with Phase 2b data

Wednesday 15:50-17:20

II-74Franziska Isabelle Kluwe

Joint model for the characterisation of cefuroxime pharmacokinetics in synovial fluid, interstitial fluid of muscle tissue and plasma

Wednesday 15:50-17:20

II-75Wojciech Krzyzanski

Implementation of delay differential equations in NONMEM

Wednesday 15:50-17:20

II-76Gilbert Koch

Characterization of postnatal sodium fluctuation in very preterm neonates

Wednesday 15:50-17:20

II-77Catherine Sherwin

Tacrolimus population pharmacokinetics in paediatric kidney transplant patients

Wednesday 15:50-17:20